News

Teva Pharmaceutical Industries Ltd. and Shanghai Fosun Pharmaceutical (Group) Co., Ltd. announced that the companies, through their respective subsidiaries, have entered a strategic…
Read More...

Averoa announced that the European Commission (EC) has granted marketing authorization for XOANACYL. This follows the positive opinion issued in March by the committee for Medicinal…
Read More...

As metabolic dysfunction-associated steatohepatitis (MASH) emerges as one of the most dangerous and underdiagnosed drivers of liver failure – affecting more than 250 million people…
Read More...

SpliceBio, a clinical-stage genetic medicines company pioneering Protein Splicing to address diseases caused by mutations in large genes, announced the close of a $135 million Series B…
Read More...

Capsida Biotherapeutics announced the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application for CAP-003, its potential best-in-class…
Read More...

Novo Nordisk announced that it will advance subcutaneous and oral amycretin into phase 3 development in weight management based on completed clinical studies. The decision to advance…
Read More...

 BioNTech SE and CureVac N.V. announced that they have entered into a definitive Purchase Agreement pursuant to which BioNTech intends to acquire all of the shares of CureVac, a…
Read More...

AbbVie announced that the U.S. Food and Drug Administration (FDA) approved a label expansion for MAVYRET (glecaprevir/pibrentasvir), an oral pangenotypic direct acting antiviral (DAA)…
Read More...

Merck, known as MSD outside of the United States and Canada, announced the U.S. Food and Drug Administration (FDA) has approved ENFLONSIA™ (clesrovimab-cfor) for the prevention of…
Read More...

YolTech Therapeutics, a clinical-stage biotechnology company developing in vivo genome editing therapies, announced that the U.S. Food and Drug Administration (FDA) has cleared the…
Read More...

A fixed-duration regimen of AstraZeneca’s Calquence (acalabrutinib) in combination with venetoclax, with or without obinutuzumab, has been approved in the European Union (EU) for the…
Read More...

Aytu BioPharma, Inc. announced the signing of an exclusive agreement to commercialize EXXUA (gepirone) extended-release tablets ("EXXUA") in the United States. Gepirone is a new…
Read More...

Alnylam Pharmaceuticals, Inc. announced that the European Commission (EC) has granted approval for the treatment of wild-type or hereditary transthyretin amyloidosis in adult patients…
Read More...

WuXi Biologics announced that it has kicked off construction of its new microbial manufacturing site for commercial production in the Wenjiang district of Chengdu, a renowned, vibrant…
Read More...

Cellectar Biosciences, Inc., a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for the treatment of cancer, announced that the U.S. Food…
Read More...

Vividion Therapeutics, Inc. (Vividion), a clinical-stage biopharmaceutical company, and a wholly owned and independently operated subsidiary of Bayer AG, announced it has secured…
Read More...

Camurus and Eli Lilly and Company have entered a collaboration and license agreement, granting Lilly exclusive, worldwide rights to the research, development, manufacture, and…
Read More...

SpyGlass Pharma, a privately held ophthalmic biotechnology company, announced the closing of a $75 million Series D financing round. SpyGlass’ Drug Delivery Platform aims to provide…
Read More...

Roche announced that the European Commission (EC) has approved a label extension for Evrysdi (risdiplam) to include a new, room-temperature stable tablet for people living with spinal…
Read More...

Agenus Inc. announced it has signed definitive partnership agreements with Zydus Lifesciences Ltd., including its subsidiaries/affiliates, hereafter referred to as “Zydus,” designed to…
Read More...